CING Stock Overview
A biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cingulate Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$152.40 |
| 52 Week Low | US$1.80 |
| Beta | -0.91 |
| 11 Month Change | -3.23% |
| 3 Month Change | -34.68% |
| 1 Year Change | -94.35% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.61% |
Recent News & Updates
Shareholder Returns
| CING | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.3% | 4.2% | 2.0% |
| 1Y | -94.4% | 13.7% | 32.4% |
Return vs Industry: CING underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: CING underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| CING volatility | |
|---|---|
| CING Average Weekly Movement | 17.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CING's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CING's weekly volatility has decreased from 56% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 13 | Shane Schaffer | www.cingulate.com |
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety.
Cingulate Inc. Fundamentals Summary
| CING fundamental statistics | |
|---|---|
| Market cap | US$14.01m |
| Earnings (TTM) | -US$16.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs CING overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CING income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$10.10m |
| Gross Profit | -US$10.10m |
| Other Expenses | US$6.25m |
| Earnings | -US$16.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CING perform over the long term?
See historical performance and comparison